Antibody Therapy and Diagnosis of Alzheimer's Disease (AD)

Alzheimer's Disease (AD) is the main neurodegenerative disease worldwide affecting more than 29 Mill. people. By 2050 the prevalence will quadruple, by thich time 1 in 85 persons worldwide will be living with AD. AD still features high growth potential and room for further innovation due to the huge worldwide growth of the number of patients and the lack of efficacious drugs.

Scientists at the University of Göttingen developed a novel proprietary Antibody for the Therapy and/or Diagnosis of Alzheimer's Disease (AD). HALLMARKS * New proprietary Antibody against Alzheimer's Disease (9D5 mouse anti human). * Antibody selectively targets pyro-Glu-Abeta peptide oligomers. * Oligomeric pyro-Glu-Abeta peptides are the triggers of Abeta aggregation and plaque formation, thus of AD. * Intraneuronal pyro-Glu-Abeta 3-42 peptide is toxic and triggers neurodegeneration and lethal neurological deficits. * To be used for sporadic AD and most familiar AD forms. * Blood ELISA test for diagnosis achieved. * In vivo proof of concept successfully achieved. USES (1) Diagnosis * Blood sample. * ELISA quick and easy measurement. * Companion therapeutical efficacy test. (2) Therapeutic * AD therapy based on proprietary antibody. We are now looking for companies, which are interested in licensing, developing and commercializing our approach.

Further Information: PDF

MBM ScienceBridge GmbH
Phone: (0551) 30724-151

Contact
Dr. Jens-Peter Horst